No profile data available.
Monte Rosa Therapeutics, Inc. (GLUE) is a healthcare company in the autoimmune treatment pharmaceuticals industry, based in Boston, United States, with about 173 full-time employees.
It reported revenue of $123.67 million for fiscal year 2025, up 63.5% from fiscal year 2024, and net income of -$38.63 million. Its market capitalization was $878.73 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins.
Monte Rosa Therapeutics reported $123.67 million in revenue for fiscal year 2025, up 63.5% from $75.62 million in fiscal year 2024.
$878.73 million as of October 9, 2026.
Listed companies of a similar size in the same industry (autoimmune treatment pharmaceuticals) include Zenas BioPharma, Inc. (ZBIO), Alumis Inc. (ALMS), Rigel Pharmaceuticals, Inc. (RIGL), Climb Bio Inc (CLYM).